Development of a modular chemical linking strategy for bispecific antibodies to suppress neuroinflammation in Alzheimer's disease via microglial polar
Development of a modular chemical linking strategy for bispecific antibodies to suppress neuroinflammation in Alzheimer's disease via microglial polar
批准号:
2273841
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2019
资助国家:
英国
项目状态:
已结题
起止时间:
2019 至 --
中文摘要
博士项目战略主题:全面了解健康的生物科学小胶质细胞是大脑中常驻的巨噬细胞,由于大脑中缺乏抗体,它们在巨噬细胞中具有独特的反应能力。小胶质细胞可以被极化成两种状态,促炎症的M1状态和抗炎的M2状态,并且可以位于M1和M2状态之间的任何位置。在阿尔茨海默病(AD)中,小胶质细胞极化为促炎、吞噬的M1表型,是由致病的、错误折叠的蛋白质介导的。补体系统可通过多种途径(经典途径、凝集素途径或替代途径)吞噬细胞。传统上,人们认为小胶质细胞补体系统仅用于清除病原体和细胞碎片。然而,它被发现在发育中的大脑中通过神经元调理的突触修剪在神经元电路的适当成熟中起着至关重要的作用。在AD中,淀粉样β-斑块通过小胶质细胞极化成炎性M1表型来激活补体途径,这既激活了经典的补体系统,又释放了激活反应性(A1)星形胶质细胞的细胞因子,从而调节了替代补体系统。在AD患者中,小胶质细胞补体系统的异常激活导致突触的调理和伴随的吞噬作用,以及随后的神经变性。在PD-1基因敲除的小鼠脊髓损伤(SCI)后,PD-1缺乏可诱导促炎的M1小胶质细胞。而在野生型小鼠中,PD-1的表达上调,并存在抗炎的M2小胶质细胞,导致更好地从脊髓损伤中恢复。基于此,我们认为,通过上调AD脑中的PD-1信号,可以通过抑制小胶质细胞补体系统来减少神经炎症和神经变性。从表达PD-L1的癌细胞中获得灵感,通过激活PD-1信号通路来逃避T细胞的免疫反应,人们相信小胶质细胞的补体反应也可以以类似的方式受到抑制。通过设计具有淀粉样β斑块靶向结构域和PD-L1结构域的双特异性抗体(BsAb),提出了小胶质细胞可以在斑块周围的局部环境中交替激活到抗炎M2状态,这些小胶质细胞将迁移到淀粉样β斑块并极化为炎性M1表型。这将通过bsAb的PD-L1结构域与小胶质细胞的PD-1结构域的相互作用来实现,从而抑制神经炎症。目前临床试验中的大多数bsAbs是通过使用灵活的多肽连接这些结构域的bsAbs而产生的,然而,这种方法并不适用于所有的bsAb构建体。因此,我们的目的是设计一种稳健的化学连接策略,该策略不仅可以用于所描述的模型bsAb,而且还可以应用于使用现有基于表达式的连接策略无法访问的许多bsAb。这将通过模块化链接策略实现,定位于独特的活性残基,这些残基将被工程到或自然发生在单独的蛋白质结构域中。如果成功,这种方法可以扩展到其他疾病模型,这些疾病模型受益于靶向治疗的生产bsAb构建物,例如其他神经退行性疾病或癌症。
英文摘要
PhD project strategic theme: Biosciences for an integrated understanding of healthMicroglia are the resident macrophages of the brain and due to the lack of antibodies in the brain, they are uniquely reactive amongst macrophages. Microglia can be polarised into two states, a pro-inflammatory, M1, and anti-inflammatory, M2 state, and can sit anywhere on the spectrum between the M1 and M2 states. In Alzheimer's disease (AD), microglial polarisation to a pro-inflammatory, M1 phenotype which is phagocytic, is mediated by pathogenic, misfolded proteins. The complement system enables phagocytosis through multiple pathways (classical, lectin or alternative). Traditionally it was believed that the microglial complement system was utilised solely to clear pathogens and cellular debris. However, it has been found to have a crucial role in the proper maturation of neuronal circuits in the developing brain through synaptic pruning via opsonisation of neurons.In AD, amyloid-beta plaques activate the complement pathway through polarisation of microglia to inflammatory M1 phenotypes which both activates the classical complement system and releases cytokines which activate reactive (A1) astrocytes, which mediate the alternative complement system. In combination, the aberrant activation of the microglial complement system leads to the opsonisation and concomitant phagocytosis of synapses and subsequent neurodegeneration in AD patients. It has been shown that PD-1 deficiency induces pro-inflammatory M1 microglia after spinal cord injury (SCI) in PD-1 knockout mice. Whilst in wildtype mice, PD-1 expression is upregulated and anti-inflammatory M2 microglia were present, leading to better recovery from SCI. Based on this, we propose that upregulating PD-1 signalling in the AD brain, a reduction in neuroinflammation and neurodegeneration could be achieved through suppression of the microglial complement system. Taking inspiration from cancer cells, which express PD-L1 to evade the immune response of T cells through activating the PD-1 signalling pathway, it is believed the microglial complement response could be suppressed in a similar way. By designing a bispecific antibody (bsAb) with an amyloid-beta plaque targeting domain and a PD-L1 domain, it is proposed that microglia which would migrate to amyloid-beta plaques and become polarised to the inflammatory M1 phenotype could be alternatively activated to the anti-inflammatory M2 state in the local environment surrounding the plaques. This would be achieved through the interaction of the PD-L1 domain of the bsAb with the PD-1 domain of the microglia, and thus suppress neuroinflammation.The majority bsAbs currently in clinical trials are produced through recombinant expression of bsAbs using a flexible peptide to link the domains, however, this approach is not suitable for all bsAb constructs. Therefore, the intention is to design a robust chemical linking strategy that can be used not only for the model bsAb described but can also be applied to a number of bsAbs which are inaccessible using current expression based linking strategies. This will be achieved via a modular linking strategy, site-specifically targeting uniquely reactive residues which will be engineered into, or naturally occuring, in the separate protein domains. If successful, this approach could be extended to other disease models which benefit from the production bsAb constructs for targeted therapies, such as other neurodegenerative conditions or cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
变形的约化密度矩阵及其全息对偶的研究
-
批准号:12005069
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:龙江
-
依托单位:
基于Modular积图和最大团的草图形状匹配技术研究
-
批准号:61305091
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2013
-
负责人:梁爽
-
依托单位: